Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals logoLexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company's other programs include LX1033, LX2931 and LX7101.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LXRX
  • CUSIP: 52887210
Key Metrics:
  • Previous Close: $15.37
  • 50 Day Moving Average: $14.58
  • 200 Day Moving Average: $15.79
  • 52-Week Range: $8.81 - $19.62
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.73
  • P/E Growth: -0.18
  • Market Cap: $1.64B
  • Outstanding Shares: 104,036,000
  • Beta: 0.6
Profitability:
  • Net Margins: -11.87%
  • Return on Equity: -9.46%
  • Return on Assets: -3.80%
Debt:
  • Debt-to-Equity Ratio: 0.46%
  • Current Ratio: 2.34%
  • Quick Ratio: 2.34%
Additional Links:
Companies Related to Lexicon Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX) (?)
Ratings Breakdown: 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $24.33 (54.79% upside)

Analysts' Ratings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Show:
DateFirmActionRatingPrice TargetDetails
2/8/2017WedbushReiterated RatingOutperform$33.00View Rating Details
1/27/2017Needham & Company LLCReiterated RatingBuyView Rating Details
12/25/2016Citigroup Inc.Set Price TargetBuy$24.00View Rating Details
12/23/2016Cowen and CompanyReiterated RatingMarket PerformView Rating Details
11/2/2016HC WainwrightReiterated RatingBuyView Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$25.00 -> $26.00View Rating Details
5/5/2016J P Morgan Chase & CoReiterated RatingHold$16.00View Rating Details
9/28/2015GabelliUpgradeSell -> Hold$13.50View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
11/1/2016Q316($0.49)($0.35)$9.68 million$27.70 millionViewN/AView Earnings Details
8/4/2016Q216($0.41)($0.37)$12.36 million$20.10 millionViewN/AView Earnings Details
5/3/2016Q1($0.30)($0.34)$11.11 million$12.50 millionViewN/AView Earnings Details
3/1/2016Q415($0.38)$0.76$21.50 million$127.30 millionViewN/AView Earnings Details
11/6/2015Q3($0.36)($0.34)$0.45 millionViewN/AView Earnings Details
8/7/2015Q215($0.32)($0.27)$0.45 million$376.00 millionViewN/AView Earnings Details
4/29/2015Q115($0.04)($0.04)$1.10 million$1.78 millionViewN/AView Earnings Details
11/4/2014Q3($0.05)($0.08)$0.16 million$0.40 millionViewN/AView Earnings Details
8/7/2014Q214($0.05)($0.05)$0.13 million$0.68 millionViewN/AView Earnings Details
5/8/2014Q114($0.05)($0.06)$0.12 million$277.00 millionViewN/AView Earnings Details
2/28/2014Q413($0.06)($0.03)$1.66 million$1.40 millionViewN/AView Earnings Details
11/12/2013Q3($0.01)($0.06)$1.59 million$0.24 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.05)($0.05)$0.37 million$0.22 millionViewN/AView Earnings Details
11/6/2012Q312($0.06)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Current Year EPS Consensus Estimate: $-1.57 EPS
Next Year EPS Consensus Estimate: $-1.80 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.37)($0.37)($0.37)
Q2 20161($0.35)($0.35)($0.35)
Q3 20161($0.46)($0.46)($0.46)
Q4 20161($0.51)($0.51)($0.51)
Q1 20171($0.62)($0.62)($0.62)
Q2 20171($0.58)($0.58)($0.58)
Q3 20171($0.47)($0.47)($0.47)
Q4 20171($0.50)($0.50)($0.50)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Insider Ownership Percentage: 5.40%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2016James F TessmerVPSell1,500$15.00$22,500.00View SEC Filing  
5/23/2016James F TessmerVPSell6,000$13.00$78,000.00View SEC Filing  
12/12/2014C.V. InvusDirectorBuy150,000$0.88$132,000.00View SEC Filing  
12/10/2014C.V. InvusDirectorBuy315,896$0.90$284,306.40View SEC Filing  
11/26/2014International S.C.A. ArtalDirectorBuy149,253,731$1.01$150,746,268.31View SEC Filing  
10/23/2012International S.C.A. ArtalDirectorBuy3,000,000$2.25$6,750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Lexicon Pharmaceuticals (NASDAQ:LXRX)
DateHeadline
News IconThe Analysts Set Lexicon Pharmaceuticals, Inc. (LXRX) Target Price ... - Petro Global News 24 (NASDAQ:LXRX)
petroglobalnews24.com - February 25 at 8:13 AM
News IconTechnical Roundup on Shares of Lexicon Pharmaceuticals Inc (LXRX) - Sherwood Daily (NASDAQ:LXRX)
sherwooddaily.com - February 23 at 6:46 AM
News IconLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Daily Sentiment Score At 0.437 - Stock Observer (NASDAQ:LXRX)
www.thestockobserver.com - February 23 at 6:46 AM
News IconLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Daily Sentiment Score At 0.435 - Stock Observer (NASDAQ:LXRX)
www.thestockobserver.com - February 22 at 8:08 AM
News IconLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Quarterly EPS At $-0.5 - Stock Observer (NASDAQ:LXRX)
www.thestockobserver.com - February 19 at 5:32 PM
News IconShare Watch: Examining the Levels for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Sherwood Daily (NASDAQ:LXRX)
sherwooddaily.com - February 17 at 1:53 PM
News IconEquity Focus: Looking at Shares of Lexicon Pharmaceuticals Inc. (LXRX) - Baldwin Journal (NASDAQ:LXRX)
baldwinjournal.com - February 17 at 1:53 PM
seekingalpha.com logoThe Long Case For Lexicon Pharmaceuticals - Seeking Alpha (NASDAQ:LXRX)
seekingalpha.com - February 17 at 1:53 PM
News IconWatching the Levels for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Midway Monitor (NASDAQ:LXRX)
midwaymonitor.com - February 15 at 12:58 AM
News IconLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Daily Sentiment Score At 0.385 - Stock Observer (NASDAQ:LXRX)
www.thestockobserver.com - February 15 at 12:58 AM
fool.com logo3 Stocks We're Watching in the First Quarter (NASDAQ:LXRX)
www.fool.com - February 14 at 4:42 PM
finance.yahoo.com logoLexicon To Present At The Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:LXRX)
finance.yahoo.com - February 13 at 7:29 PM
News IconKeeping Tabs on Levels for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Davidson Register (NASDAQ:LXRX)
davidsonregister.com - February 13 at 10:33 AM
News IconChecking the Levels on Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Baldwin Journal (NASDAQ:LXRX)
baldwinjournal.com - February 10 at 7:14 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals (NASDAQ:LXRX)
finance.yahoo.com - February 9 at 7:25 PM
News IconLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:LXRX)
www.thestockobserver.com - February 8 at 12:43 AM
investornewswire.com logoEPS Projection For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Set At $-0.5 - Investor Newswire (NASDAQ:LXRX)
www.investornewswire.com - February 8 at 12:43 AM
News IconQuarterly EPS Of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ... - Stock Observer (NASDAQ:LXRX)
www.thestockobserver.com - February 5 at 6:10 PM
stockhouse.com logoResearch Reports Coverage on Biotech Stocks -- Anavex Life Sciences, Omeros, Spectrum Pharma, and Lexicon Pharma (NASDAQ:LXRX)
www.stockhouse.com - February 2 at 7:10 PM
News IconMA Levels in Review for Lexicon Pharmaceuticals Inc. (LXRX) - Market Point (NASDAQ:LXRX)
mtptnews.com - January 31 at 12:07 AM
News IconTraders Are Bearish Lexicon Pharmaceuticals, Inc. (LXRX) After The Stock Formed Head & Shoulders Pattern (NASDAQ:LXRX)
randolphguide.com - January 30 at 7:06 PM
News IconStock Perspective: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Company Earnings Watch - Aiken Advocate (NASDAQ:LXRX)
aikenadvocate.com - January 26 at 8:14 PM
News IconFocusing on the Numbers for Lexicon Pharmaceuticals Inc. (LXRX) - Market Point (NASDAQ:LXRX)
mtptnews.com - January 26 at 8:14 PM
News IconLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Bearish Target At $33 - Stock Observer (NASDAQ:LXRX)
www.thestockobserver.com - January 26 at 8:14 PM
seekingalpha.com logo2 Key Events On The Horizon For Lexicon Pharmaceuticals - Seeking Alpha (NASDAQ:LXRX)
seekingalpha.com - January 26 at 8:14 PM
News IconEarnings According to Analysts for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)? - Aiken Advocate (NASDAQ:LXRX)
aikenadvocate.com - January 19 at 8:17 PM
News IconLexicon Pharmaceuticals Inc LXRX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:LXRX)
www.bioportfolio.com - January 13 at 7:40 PM
News IconStock Getting Tripped Up In Session: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Wall Street Beacon (NASDAQ:LXRX)
wsbeacon.com - January 11 at 3:15 PM
News IconStock Reaching Most Volatile List Today: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Wall Street Beacon (NASDAQ:LXRX)
wsbeacon.com - January 11 at 3:15 PM
News IconLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Daily Sentiment Score At 0.187 - Stock Observer (NASDAQ:LXRX)
www.thestockobserver.com - January 11 at 5:21 AM
News IconTop Stock With Upside & Growth Potential: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Prospect Journal (NASDAQ:LXRX)
prospectjournal.com - January 10 at 12:10 AM
prnewswire.com logoLexicon To Present At The 35th Annual J.P. Morgan Healthcare ... - PR Newswire (press release) (NASDAQ:LXRX)
www.prnewswire.com - January 6 at 5:50 AM
News IconBearish Target Of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) At $33 - Stock Observer (NASDAQ:LXRX)
www.thestockobserver.com - January 5 at 7:48 PM
finance.yahoo.com logoLexicon To Present At The 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:LXRX)
finance.yahoo.com - January 5 at 7:48 PM
News IconDaily Sentiment Score Of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) At -0.217 - Stock Observer (NASDAQ:LXRX)
www.thestockobserver.com - January 3 at 8:26 PM
News IconAre There Catalysts to Propel This Stock Forward: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Prospect Journal (NASDAQ:LXRX)
prospectjournal.com - January 2 at 6:19 PM
News IconInvestor Watch: Looking at Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Wall Street Beacon (NASDAQ:LXRX)
wsbeacon.com - December 29 at 9:25 AM
News IconStock Tracker: Focusing on Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Wall Street Beacon (NASDAQ:LXRX)
wsbeacon.com - December 24 at 9:30 AM
News IconBlog Coverage Lexicon Pharmas Tandem2 Phase 3 Clinical Trial of Sotagliflozin Met its Primary Endpoint (NASDAQ:LXRX)
www.fox8live.com - December 23 at 6:35 PM
prnewswire.com logoLexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For ... (NASDAQ:LXRX)
www.prnewswire.com - December 22 at 6:43 PM
finance.yahoo.com logoBlog Coverage Lexicon Pharma's Tandem2 Phase 3 Clinical Trial of Sotagliflozin Met its Primary Endpoint (NASDAQ:LXRX)
finance.yahoo.com - December 22 at 6:42 PM
News IconStock Checkup: Technical Watch on Lexicon Pharmaceuticals Inc. (LXRX) - StockTalk Daily (NASDAQ:LXRX)
stocktalkdaily.com - December 22 at 12:18 AM
News IconEnterprise Value Review for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Wall Street Beacon (NASDAQ:LXRX)
wsbeacon.com - December 22 at 12:18 AM
streetinsider.com logoLexicon Pharma (LXRX) Pivotal inTandem2 Phase 3 Trial for Sotagliflozin Met Primary Endpoint (NASDAQ:LXRX)
www.streetinsider.com - December 21 at 7:15 PM
us.rd.yahoo.com logo6:45 am Lexicon Pharma reports 'positive' top-line results in second pivotal phase 3 study for sotagliflozin in patients with type 1 diabetes; study met its primary endpoint (NASDAQ:LXRX)
us.rd.yahoo.com - December 21 at 7:15 PM
News IconMF Rank Review for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Business Daily Leader (NASDAQ:LXRX)
businessdailyleader.com - December 21 at 8:00 AM
streetinsider.com logoLexicon Pharma (LXRX) Pivotal inTandem2 Phase 3 Trial for Sotagliflozin Met Primary Endpoint - StreetInsider.com (NASDAQ:LXRX)
www.streetinsider.com - December 21 at 8:00 AM
finance.yahoo.com logoLexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes (NASDAQ:LXRX)
finance.yahoo.com - December 21 at 8:00 AM
capitalcube.com logoLexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : December 19, 2016 (NASDAQ:LXRX)
www.capitalcube.com - December 20 at 12:07 PM
News IconNotable Friday Option Activity: LXRX, WTW, XBIT (NASDAQ:LXRX)
www.stockoptionschannel.com - December 16 at 6:59 PM

Social

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Where is Lexicon Pharmaceuticals' stock going? Where will Lexicon Pharmaceuticals' stock price be in 2017?

7 brokers have issued 12 month price objectives for Lexicon Pharmaceuticals' stock. Their forecasts range from $16.00 to $33.00. On average, they expect Lexicon Pharmaceuticals' stock price to reach $24.33 in the next year.

When will Lexicon Pharmaceuticals announce their earnings?

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Lexicon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:

  • According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (2/17/2017)

  • Needham & Company LLC analysts commented, "Telotristat is under review by FDA for treatment of Carcinoid Syndrome. We expect approval by 2/28/17 PDUFA date. Phase 3 registration trial met its primary endpoint of reduction in BM frequency, with trends towards reduction in flushing and abdominal pain. No FDA AdCom mtg was held. Lexicon has built commercial infrastructure and plans to market telotristat by itself. We estimate peak U.S. sales in the range of $250-300M. Most ex-U.S. rights to telotristat were out- licensed to Ipsen, which has submitted an MAA." (1/27/2017)

Who owns Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Artal Group S.A. (55.29%), FMR LLC (15.00%), State Street Corp (1.53%), Loomis Sayles & Co. L P (0.81%), Teachers Retirement System of The State of Kentucky (0.54%) and GSA Capital Partners LLP (0.14%).

Who sold Lexicon Pharmaceuticals stock? Who is selling Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Teachers Retirement System of The State of Kentucky, Loomis Sayles & Co. L P, Pacad Investment Ltd., AQR Capital Management LLC, Tudor Investment Corp Et Al and Paradigm Asset Management Co. LLC.

Who bought Lexicon Pharmaceuticals stock? Who is buying Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Russell Investments Group Ltd., Advisory Research Inc., GSA Capital Partners LLP, Putnam Investments LLC, A.R.T. Advisors LLC, FMR LLC and Numeric Investors LLC.

How do I buy Lexicon Pharmaceuticals stock?

Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Lexicon Pharmaceuticals stock cost?

One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $15.72.

Lexicon Pharmaceuticals (NASDAQ:LXRX) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Earnings History Chart

Earnings by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Dividend History Chart

Dividend Payments by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Last Updated on 2/25/2017 by MarketBeat.com Staff